Abstract

BackgroundAccumulating studies have demonstrated the abnormal expressions and prognostic values of certain members of the tripartite motif (TRIM) family in diverse cancers. However, comprehensive prognostic values of the TRIM family in hepatocellular carcinoma (HCC) are yet to be clearly defined.MethodsThe prognostic values of the TRIM family were evaluated by survival analysis and univariate Cox regression analysis based on gene expression data and clinical data of HCC from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. The expression profiles, protein–protein interaction among the TRIM family, prediction of transcription factors (TFs) or miRNAs, genetic alterations, correlations with the hallmarks of cancer and immune infiltrates, and pathway enrichment analysis were explored by multiple public databases. Further, a TRIM family gene-based signature for predicting overall survival (OS) in HCC was built by using the least absolute shrinkage and selection operator (LASSO) regression. TCGA–Liver Hepatocellular Carcinoma (LIHC) cohort was used as the training set, and GSE76427 was used for external validation. Time-dependent receiver operating characteristic (ROC) and survival analysis were used to estimate the signature. Finally, a nomogram combining the TRIM family risk score and clinical parameters was established.ResultsHigh expressions of TRIM family members including TRIM3, TRIM5, MID1, TRIM21, TRIM27, TRIM32, TRIM44, TRIM47, and TRIM72 were significantly associated with HCC patients’ poor OS. A novel TRIM family gene-based signature (including TRIM5, MID1, TRIM21, TRIM32, TRIM44, and TRIM47) was built for OS prediction in HCC. ROC curves suggested the signature’s good performance in OS prediction. HCC patients in the high-risk group had poorer OS than the low-risk patients based on the signature. A nomogram integrating the TRIM family risk score, age, and TNM stage was established. The ROC curves suggested that the signature presented better discrimination than the similar model without the TRIM family risk score.ConclusionOur study identified the potential application values of the TRIM family for outcome prediction in HCC.

Highlights

  • Liver cancer is ranked as the sixth most common malignancy and is the fourth leading cause of cancer-related deaths with an estimated 841,000 new cases and 782,000 deaths occurring worldwide in 2018 [1]

  • All genes in the tripartite motif (TRIM) family were subjected to the analysis, and nine genes including TRIM3, TRIM5, MID1, TRIM21, TRIM27, TRIM32, TRIM44, TRIM47, and TRIM72 were identified as genes that might be associated with Hepatocellular carcinoma (HCC) patients’ overall survival (OS) in both TCGA-LIHC and GSE76427 (p < 0.05, Figures 1B, C)

  • The results showed that five recognized prognostic biomarkers (PDCD10, TFAP4, LYRM4, VPS35, and PPM1D) were prognosis-associated in TCGA-LIHC, and VPS35 was related to prognosis in both TCGA-LIHC and GSE76427 with an HR > 1 (p < 0.05)

Read more

Summary

Introduction

Liver cancer is ranked as the sixth most common malignancy and is the fourth leading cause of cancer-related deaths with an estimated 841,000 new cases and 782,000 deaths occurring worldwide in 2018 [1]. Hepatocellular carcinoma (HCC), the major histological type of liver cancer, is related to well-known risk factors, including hepatitis virus (B and C) infections, aflatoxin B1 exposure, alcohol abuse, and smoking, etc [2]. Though the selected HCC patients have received surgical resection, their prognoses remain unsatisfactory due to the high incidence of recurrence [4, 5]. Predicting the prognosis accurately may be of use for choosing effective personalized treatment, prolonging the survival time for patients with HCC. Identification of novel biomarkers for outcome prediction is of great importance for HCC. Accumulating studies have demonstrated the abnormal expressions and prognostic values of certain members of the tripartite motif (TRIM) family in diverse cancers. Comprehensive prognostic values of the TRIM family in hepatocellular carcinoma (HCC) are yet to be clearly defined

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call